Infliximab + Infliximab + Infliximab
ApprovedRecruiting 1 views this week 0 watching⚡ Active
Interest: 50/100
50
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Inflammatory Bowel Diseases
Conditions
Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis
Trial Timeline
Apr 9, 2024 → Nov 1, 2026
NCT ID
NCT06113913About Infliximab + Infliximab + Infliximab
Infliximab + Infliximab + Infliximab is a approved stage product being developed by Celltrion for Inflammatory Bowel Diseases. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06113913. Target conditions include Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis.
What happened to similar drugs?
9 of 20 similar drugs in Inflammatory Bowel Diseases were approved
Approved (9) Terminated (3) Active (11)
Hype Score Breakdown
Clinical
20
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06113913 | Approved | Recruiting |
Competing Products
20 competing products in Inflammatory Bowel Diseases
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| CT-P13 | Celltrion | Phase 3 | 36 |
| Subcutaneous infliximab CT-P13 Remsima®SC | Celltrion | Pre-clinical | 22 |
| Infliximab subcutaneous + Immunosuppressive Agents | Celltrion | Phase 3 | 47 |
| fidaxomicin | Astellas Pharma | Approved | 43 |
| Eribulin + Adriamycin + Cyclophosphamide | Eisai | Phase 2 | 39 |
| E6007 + E6007 + E6007 + E6007 + E6007 + E6007 | Eisai | Phase 1 | 29 |
| Placebo + MORF-057 | Eli Lilly | Phase 2 | 42 |
| Baricitinib + Baricitinib | Eli Lilly | Phase 2 | 35 |
| LY3114062 SC + Placebo + LY3114062 IV | Eli Lilly | Phase 1 | 29 |
| MORF-057 + Placebo | Eli Lilly | Phase 2 | 39 |
| MORF-057 | Eli Lilly | Phase 2 | 35 |
| LY3009104 | Eli Lilly | Phase 1 | 29 |
| HRF2105 patch + Loxoprofen patch + placebo | Jiangsu Hengrui Medicine | Phase 2 | 31 |
| Risankizumab | AbbVie | Approved | 43 |
| GC012F Injection infusion | AstraZeneca | Phase 1 | 36 |
| AZD6793 + Placebo | AstraZeneca | Phase 1 | 29 |
| Human Papillomavirus Vaccine | Merck | Approved | 43 |
| Pembrolizumab | Merck | Phase 2 | 31 |
| Gardasil vaccine | Merck | Pre-clinical | 26 |
| Bezlotoxumab | Merck | Approved | 35 |